Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Helsinki | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
The study is a randomised controlled trial comparing the effectivity and impact of epidural analgesia and wound catheter analgesia in patients undergoing pancreaticoduodenectomy. The aim of the study is to examine whether there are a difference in perioperative fluid therapy and complication rates between the patients in epidural and wound catheter groups.
All patients undergoing pancreaticoduodenectomy in Helsinki University Hospital are recruited in the study. Patients meeting the inclusion criteria and giving consent to participate the study will be randomised to whether epidural analgesia group or wound catheter analgesia group. Both groups receive additional analgesia with intravenous PCA-oxycodone (patient controlled analgesia).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Epidural analgesia | Active Comparator |
| |
| Wound catheter analgesia | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Analgesia via epidural catheter | Procedure | Ropivacain-infusion 2 mg/ml 1,25ml/h/10kg IBW (ideal body weight) is started to patients in the beginning of the surgery and is continued to POD 4. The rest of the treatment obey study protocol in both groups. |
| Measure | Description | Time Frame |
|---|---|---|
| The norepinephrine consumption | Norepinephrine consumption on POD 0 | Postoperative day 0 |
| Measure | Description | Time Frame |
|---|---|---|
| Fluid volumes on PODs 0-4 | Intraoperative and postoperative fluid volumes | Postoperative days 0-4 |
| Oxycodone consumption | Intravenous PCA opioid consumption. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Helsinki University Hospital | Helsinki | HUS | 00029 | Finland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010182 | Pancreatic Diseases |
| D010190 | Pancreatic Neoplasms |
| D011183 | Postoperative Complications |
| ID | Term |
|---|---|
| D004066 | Digestive System Diseases |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Analgesia via wound catheter | Procedure | Ropivacain 5 mg/ml 2,5ml/10kg IBW (ideal body weight) is given to patients in the end of the surgery. After that ropivacain-infusion 2mg/ml 1,25ml/h/10kg IBW is started to patients and is continued to POD 4. The rest of the treatment obey study protocol in both groups. |
|
| Postoperative days 1-4 |
| Hospital length of stay | Postoperative days 0-60 |
| Postoperative complications | Clavien-Dindo complications (scale 0-5), pancreatic fistulas (ISGPF definition, grade A-C), postpancreatectomy hemorrage (IPGPS definition, grade A-C), delayed gastric emptying (ISGPS definition, grade A-C). | Postoperative days 0-90 |
| Reoperation rates | Postoperative days 0-90 |
| Readmission rates | Postoperative days 0-90 |
| Mortality | postoperative day 0-90 |
| D004701 |
| Endocrine Gland Neoplasms |
| D004700 | Endocrine System Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |